FIRST QUARTER (JANUARY -
- Oder intake
SEK 238.5 M (206.6) -
Net sales
SEK 257.2 M (230.2) -
Operating profit
SEK 45.8 M (23.7) -
Profit after tax
SEK 36.7 M (17.6) -
Earnings per share before/after dilution
SEK 1.07 (0.51) -
Cash flow
SEK 87.9 M (84.5) -
Order backlog
SEK 1,848.0 M (1,903.3) MSEK at the end of the period
SIGNIFICANT EVENTS DURING THE FIRTS QUARTER
- RayStation in more than 1,000 radiotherapy centers worldwide.
-
The Royal Marsden set to be the first center in the world to implement online adaptive radiation therapy utilizing ARTemis from
RaySearch . RaySearch acquires the product DrugLog from Pharmacolog.-
World leading carbon ion center QST in
Chiba, Japan , selects RayStation.
SIGNIFICANT EVENTS AFTER THE END OF THE REPORTING PERIOD
Raigmore Hospital inScotland selects RayCare.RaySearch and C-RAD signed collaboration agreement.- RayCare has been certified to be interoperable with Varian TrueBeam.
WEBCAST
CEO
Link to webcast:
You can also join the webcast by phone:
Sverige: +46 (0) 8 505 100 31
US: +1 (1) 631 570 56 13
The information contained in this interim report is such that
For more information, please contact:
Johan Löf, founder and CEO,
Telephone: +46 (0) 8 510 530 00
johan.lof@raysearchlabs.com
Telephone: +46 (0) 8 510 530 00
annika.henriksson@raysearchlabs.com
About
Research's software has been sold to over 1,000 clinics in 43 countries. The company was founded in 2000 as a spin-off from the
https://news.cision.com/raysearch-laboratories/r/interim-report-january-1---march-31--2024,c3983281
https://mb.cision.com/Main/1102/3983281/2803463.pdf
(c) 2024 Cision. All rights reserved., source